Anhui Medical University, Hefei, Anhui, China; The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
The First Affiliated Hospital of Anhui Medical University, Department of Clinical Laboratory, Hefei, Anhui, China.
Am J Med Sci. 2020 Apr;359(4):226-234. doi: 10.1016/j.amjms.2020.01.009. Epub 2020 Jan 21.
Hepatocellular carcinoma (HCC) is one of the most frequent cancers in the world. In this study, differentially expressed genes (DEGs) between tumor tissues and normal tissues were identified using the comprehensive analysis method in bioinformatics.
We downloaded 3 mRNA expression profiles from the Gene Expression Omnibus database to identify DEGs between tumor tissues and adjacent normal tissues. The Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis, protein-protein interaction network was performed to understand the function of DEGs. OncoLnc, which was linked to The Cancer Genome Atlas survival data, was used to investigate the prognostic values of hub genes. The expression of selected hub genes was validated by the quantitative real-time polymerase chain reaction.
A total of 235 DEGs, consisting of 36 upregulated and 199 downregulated genes, were identified between tumor tissue and normal tissue. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis results showed the upregulated DEGs to be significantly enriched in cell division, mid-body, ATP binding and oocyte meiosis pathways. The downregulated DEGs were mainly involved in epoxygenase P450 pathway, extracellular region, oxidoreductase activity and metabolic pathways. Ten hub genes, including Aurora kinase A, Cell division cycle 20, formiminotransferase cyclodeaminase, UBE2C, Cyclin B2, pituitary tumor-transforming gene 1, CDKN3, CKS1B, Topoisomerase-II alpha and KIF20A, were identified as the key genes in HCC. Survival analysis found the expression of hub genes to be significantly correlated with the survival of patients with HCC.
The present study identified hub genes and pathways in HCC that may be potential targets for diagnosis, treatment and prognostic prediction.
肝细胞癌（HCC）是世界上最常见的癌症之一。在这项研究中，我们使用生物信息学的综合分析方法，鉴定了肿瘤组织与正常组织之间的差异表达基因（DEGs）。
我们从基因表达综合数据库中下载了 3 个 mRNA 表达谱，以鉴定肿瘤组织与相邻正常组织之间的 DEGs。进行基因本体论、京都基因与基因组百科全书通路分析、蛋白质-蛋白质相互作用网络，以了解 DEGs 的功能。OncoLnc 与癌症基因组图谱生存数据相关联，用于研究关键基因的预后价值。通过定量实时聚合酶链反应验证选定的关键基因的表达。
共鉴定出 235 个 DEGs，包括 36 个上调基因和 199 个下调基因，这些基因在肿瘤组织和正常组织之间存在差异表达。基因本体论和京都基因与基因组百科全书分析结果表明，上调的 DEGs 在细胞分裂、中体、ATP 结合和卵母细胞减数分裂途径中显著富集。下调的 DEGs 主要参与环氧合酶 P450 途径、细胞外区、氧化还原酶活性和代谢途径。鉴定出 10 个关键基因，包括 Aurora 激酶 A、细胞分裂周期 20、甲硫氨酸环化酶、UBE2C、细胞周期蛋白 B2、垂体肿瘤转化基因 1、CDKN3、CKS1B、拓扑异构酶-IIα和 KIF20A，它们是 HCC 的关键基因。生存分析发现，关键基因的表达与 HCC 患者的生存显著相关。
本研究鉴定了 HCC 中的关键基因和途径，它们可能是诊断、治疗和预后预测的潜在靶点。
